National Cancer Institute, Av. Presidente Julio A. Roca 781, C 1067 Ciudad Autónoma de Buenos Aires, Argentina.
National Cancer Institute, Av. Presidente Julio A. Roca 781, C 1067 Ciudad Autónoma de Buenos Aires, Argentina.
Cancer Epidemiol. 2022 Aug;79:102200. doi: 10.1016/j.canep.2022.102200. Epub 2022 Jun 8.
Cancer is an important risk factor in patients with COVID-19. We aimed to describe the clinical and demographic characteristics associated with mortality in patients with cancer who were infected with SARS-CoV-2.
We conducted a retrospective longitudinal study of 1206 patients with confirmed SARS-CoV-2 infection and cancer, registered in the Argentinean Network of Hospital-Based Cancer Registries (RITA) from March 31, 2020 to January 31, 2021. Demographic and clinical differences between survivors and non-survivors were summarized using descriptive statistics. The primary endpoint was all-cause mortality within 30 days of COVID-19 diagnosis. Risk factors for mortality were identified using logistic regression models.
1206 patients with cancer and confirmed SARS-CoV-2 infection were included, median age was 54 years (interquartile range: 42-65); 793 (65.8%) were female. 1101 (91.3%) had solid tumors and 105(8.7%) had hematological malignancies. The most frequent solid tumor was breast (278, 23.1%), while lymphoma was the main hematological one (59, 4.9%). Cervical cancer was more frequent in survivors, while lung cancer predominated in non-survivors. 275 (22.8%) patients were diagnosed with cancer within the past year. A total of 129 (10.7%) patients died within 30 days after COVID-19 diagnosis, with a case fatality rate of 15.2% (16/105) for hematologic malignancies and 10.3% (113/1101) for solid tumors. Multivariable regression analysis showed that age 60-79 (odds ratio [OR]: 4.69, 95% confidence interval [CI]: 2.72-9.70), age ≥ 80 (OR: 12.86, 95%CI: 5.08-32.54), time since cancer diagnosis < 1 year (OR: 2.49, 95%CI: 1.57-3.93) and 1-2 years (OR: 2.20, 95%CI: 1.36-3.57), and lung cancer (OR: 4.35, 95%CI: 2.02-9.36) were risk factors for death.
Patients with cancer and SARS-CoV-2 infection had a high case-fatality rate. Identified risk factors (older age, recent diagnosis and lung type) could guide prevention strategies aimed at reducing the risk of dying from COVID-19 in cancer patients.
癌症是 COVID-19 患者的一个重要危险因素。本研究旨在描述感染 SARS-CoV-2 的癌症患者与死亡率相关的临床和人口统计学特征。
我们对 2020 年 3 月 31 日至 2021 年 1 月 31 日期间，在阿根廷基于医院的癌症登记网络（RITA）中登记的 1206 例确诊 SARS-CoV-2 感染合并癌症的患者进行了回顾性纵向研究。采用描述性统计方法总结幸存者和非幸存者之间的人口统计学和临床差异。主要终点是 COVID-19 诊断后 30 天内的全因死亡率。使用逻辑回归模型确定死亡的危险因素。
共纳入 1206 例癌症合并 SARS-CoV-2 感染患者，中位年龄为 54 岁（四分位距：42-65）；793 例（65.8%）为女性。1101 例（91.3%）为实体瘤患者，105 例（8.7%）为血液恶性肿瘤患者。最常见的实体瘤为乳腺癌（278 例，23.1%），而血液恶性肿瘤中主要为淋巴瘤（59 例，4.9%）。宫颈癌在幸存者中更为常见，而肺癌在非幸存者中更为常见。275 例（22.8%）患者在过去一年内被诊断为癌症。共有 129 例（10.7%）患者在 COVID-19 诊断后 30 天内死亡，血液恶性肿瘤的病死率为 15.2%（16/105），实体瘤的病死率为 10.3%（113/1101）。多变量回归分析显示，60-79 岁（比值比[OR]：4.69，95%置信区间[CI]：2.72-9.70）、≥80 岁（OR：12.86，95%CI：5.08-32.54）、癌症诊断后<1 年（OR：2.49，95%CI：1.57-3.93）和 1-2 年（OR：2.20，95%CI：1.36-3.57）以及肺癌（OR：4.35，95%CI：2.02-9.36）是死亡的危险因素。
癌症合并 SARS-CoV-2 感染患者的病死率较高。确定的危险因素（年龄较大、近期诊断和肺癌类型）可以指导旨在降低癌症患者 COVID-19 死亡风险的预防策略。
